PCSK9 and metabolic syndrome: Some reports have also correlated resistin with hypertension, with a mechanism that is not fully understood, with atherogenic dyslipidemia, by modulating SREBP1-SREBP2 pathways, and with proprotein convertase subtilisin/kexin type 9 (PCSK9).